Vitamin D suppresses proangiogenic factors in patients with ulcerative colitis: A randomized double blind placebo controlled clinical trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

This study aimed to assess the effect of vitamin D on serum levels of proangiogenic factors, visfatin and vascular endothelial growth factor (VEGF), in patients with UC.

Why It Was Studied

Angiogenesis and inflammation are involved in the pathogenesis of ulcerative colitis (UC).

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized and double-blind study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Visfatin, VEGF, and 25-hydroxyvitamin D [25(OH)D] concentrations were assessed before and 90 days after the intervention.

What Was Measured

The subject headings attached to it are Colitis, Ulcerative, Cytokines, Dietary Supplements, Inflammation, Neovascularization, Physiologic, Nicotinamide Phosphoribosyltransferase and Vascular Endothelial Growth Factor A.

Author keywords: Ulcerative colitis, Visfatin and Vitamin D.

What This Means in Plain Language

The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (Complementary therapies in clinical practice), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.